Disclaimer

Using this link will let you leave a website of Boehringer Ingelheim International GmbH (“BI”) or to a different domain under the control of BI. In the event that the linked site is not under the control of BI but under the control of a third party or an affiliate in the Boehringer Ingelheim group of companies, BI shall not be responsible for the contents, processing of personal data of any linked site or any link contained in a linked site, or any changes or updates to such sites. This link is provided to you only as a convenience, and the inclusion of any link does not imply endorsement by BI of the site.

Disclaimer

Using this link will let you leave a website of Boehringer Ingelheim International GmbH (“BI”) or to a different domain under the control of BI. In the event that the linked site is not under the control of BI but under the control of a third party or an affiliate in the Boehringer Ingelheim group of companies, BI shall not be responsible for the contents, processing of personal data of any linked site or any link contained in a linked site, or any changes or updates to such sites. This link is provided to you only as a convenience, and the inclusion of any link does not imply endorsement by BI of the site.

Disclaimer

Using this link will let you leave a website of Boehringer Ingelheim International GmbH (“BI”) or to a different domain under the control of BI. In the event that the linked site is not under the control of BI but under the control of a third party or an affiliate in the Boehringer Ingelheim group of companies, BI shall not be responsible for the contents, processing of personal data of any linked site or any link contained in a linked site, or any changes or updates to such sites. This link is provided to you only as a convenience, and the inclusion of any link does not imply endorsement by BI of the site.

Mario prides himself on quality service.

SPIRIVA® in COPD improves his quality of life

SPIRIVA® Respimat® significantly improved quality of life (QoL)*

The proportion of responders (those whose total SGRQ scores fell by ≥4 units from baseline) was significantly higher in the SPIRIVA® Respimat® group than the placebo group (-4.7 vs -1.8 units, respectively)

*The St. George’s Respiratory Questionnaire (SGRQ) is a recognised indicator of health-related quality of life, measuring impairment on a scale of 0 to 100. Minimal clinically important difference in SGRQ is defined as 4 units.

From a 1-year, randomised, double-blind study of COPD patients receiving SPIRIVA® Respimat® 2.5 μg administered once daily in two puffs (5 μg) or placebo. Coprimary endpoints were trough FEV1 and time to first exacerbation during the study period. Patients were allowed to take all other types of COPD treatments except for inhaled anticholinergics.

SPIRIVA® is indicated as a maintenance bronchodilator treatment to relieve symptoms of patients with chronic obstructive pulmonary disease (COPD).